EMA starts new benefit-risk assessment of flupirtine

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2017年 / 1677卷 / 1期
关键词：
D O I：
10.1007/s40278-017-38280-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 50 条
  • [21] Benefit-Risk Assessment of Orlistat in the Treatment of Obesity
    Priya Sumithran
    Joseph Proietto
    Drug Safety, 2014, 37 : 597 - 608
  • [22] Benefit-Risk Assessment of Raloxifene in Postmenopausal Osteoporosis
    Ann Cranney
    Jonathan D. Adachi
    Drug Safety, 2005, 28 : 721 - 730
  • [23] A Benefit-Risk Assessment of Caffeine as an Analgesic Adjuvant
    Wei-Ya Zhang
    Drug Safety, 2001, 24 : 1127 - 1142
  • [24] On a Stepwise Quantitative Approach for Benefit-Risk Assessment
    He, Weili
    Sun, Yaxuan
    Li, Qing
    Wan, Sabrina
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (05) : 625 - 634
  • [25] Benefit-Risk Assessment of Orlistat in the Treatment of Obesity
    Sumithran, Priya
    Proietto, Joseph
    DRUG SAFETY, 2014, 37 (08) : 597 - 608
  • [26] A Benefit-Risk Assessment of Sibutramine in the Management of Obesity
    Enzo Nisoli
    Michele O. Carruba
    Drug Safety, 2003, 26 : 1027 - 1048
  • [27] Benefit-risk assessment of vitamin D supplementation
    Bischoff-Ferrari, H. A.
    Shao, A.
    Dawson-Hughes, B.
    Hathcock, J.
    Giovannucci, E.
    Willett, W. C.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (07) : 1121 - 1132
  • [28] A Benefit-Risk Assessment of Basiliximab in Renal Transplantation
    Ugo Boggi
    Romano Danesi
    Fabio Vistoli
    Marco Del Chiaro
    Stefano Signori
    Piero Marchetti
    Mario Del Tacca
    Franco Mosca
    Drug Safety, 2004, 27 : 91 - 106
  • [29] A benefit-risk assessment of sibutramine in the management of obesity
    Nisoli, E
    Carruba, MO
    DRUG SAFETY, 2003, 26 (14) : 1027 - 1048
  • [30] Benefit-risk assessment: to quantify or not to quantify, that is the question
    Yuan, Zhong
    Levitan, Bennett
    Berlin, Jesse A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (06) : 653 - 656
12345